NASDAQ:MDGL Madrigal Pharmaceuticals (MDGL) Stock Forecast, Price & News $153.34 -6.17 (-3.87%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$151.42▼$161.7250-Day Range$153.34▼$223.0352-Week Range$57.21▼$322.67Volume393,502 shsAverage Volume368,866 shsMarket Capitalization$2.83 billionP/E RatioN/ADividend YieldN/APrice Target$309.18 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Madrigal Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.82 Rating ScoreUpside/Downside101.6% Upside$309.18 Price TargetShort InterestBearish15.15% of Float Sold ShortDividend StrengthN/ASustainability-0.92Upright™ Environmental ScoreNews Sentiment0.30Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($18.77) to ($8.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.53 out of 5 starsMedical Sector149th out of 963 stocksPharmaceutical Preparations Industry49th out of 457 stocks 4.4 Analyst's Opinion Consensus RatingMadrigal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $309.18, Madrigal Pharmaceuticals has a forecasted upside of 101.6% from its current price of $153.34.Amount of Analyst CoverageMadrigal Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted15.15% of the float of Madrigal Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMadrigal Pharmaceuticals has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Madrigal Pharmaceuticals has recently increased by 8.29%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMadrigal Pharmaceuticals does not currently pay a dividend.Dividend GrowthMadrigal Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMadrigal Pharmaceuticals has received a 73.28% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Madrigal Pharmaceuticals is -0.92. Previous Next 1.8 News and Social Media Coverage News SentimentMadrigal Pharmaceuticals has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Madrigal Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 16 people have searched for MDGL on MarketBeat in the last 30 days. This is a decrease of -16% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Madrigal Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders23.92% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.86% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($18.77) to ($8.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Madrigal Pharmaceuticals is -8.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Madrigal Pharmaceuticals is -8.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMadrigal Pharmaceuticals has a P/B Ratio of 13.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Madrigal Pharmaceuticals (NASDAQ:MDGL) StockMadrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.Read More MDGL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDGL Stock News HeadlinesSeptember 21, 2023 | msn.comObesity treatment optimism boosts Eli Lilly, Novo Nordisk while others face downturnSeptember 20, 2023 | finance.yahoo.com1 Beaten-Down Stock That Could Soar by 86%, According to Wall StreetSeptember 24, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.September 20, 2023 | americanbankingnews.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Given "Outperform" Rating at Evercore ISISeptember 20, 2023 | americanbankingnews.comAnalysts Set Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) PT at $309.18September 20, 2023 | americanbankingnews.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 19, 2023 | msn.comEvercore ISI Group Maintains Madrigal Pharmaceuticals (MDGL) Outperform RecommendationSeptember 15, 2023 | finanznachrichten.deMadrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 24, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 14, 2023 | finance.yahoo.comMadrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 13, 2023 | msn.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Jumps on Move to the Head of the FDA LineSeptember 13, 2023 | marketwatch.comMadrigal Gets FDA Priority Review of Resmetirom in NASH With Liver Fibrosis >MDGLSeptember 13, 2023 | finance.yahoo.comMadrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver FibrosisSeptember 13, 2023 | finance.yahoo.comMadrigal Pharmaceuticals Surges As Its NASH Treatment Toes The Long-Awaited Finish LineSeptember 11, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Madrigal PharmaceuticalsSeptember 11, 2023 | finanznachrichten.deMadrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive OfficerSeptember 11, 2023 | benzinga.comMadrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive OfficerSeptember 7, 2023 | finance.yahoo.com3 Biotech Stocks That Wall Street Analysts Can’t Get Enough OfSeptember 1, 2023 | markets.businessinsider.comB.Riley Financial Sticks to Its Hold Rating for Madrigal Pharmaceuticals (MDGL)August 23, 2023 | finance.yahoo.com3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy?August 20, 2023 | msn.comMadrigal's Resmetirom Nears Commercialization Despite Market ConcernsAugust 14, 2023 | finance.yahoo.comJohn Paulson's Q2 2023 13F Filing UpdateAugust 10, 2023 | seekingalpha.comMadrigal Pharmaceuticals: The NASH Market Is No Longer GuaranteedAugust 8, 2023 | finanznachrichten.deMadrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial ResultsAugust 8, 2023 | finance.yahoo.comMadrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial ResultsJuly 17, 2023 | markets.businessinsider.comJMP Securities Keeps Their Buy Rating on Madrigal Pharmaceuticals (MDGL)July 17, 2023 | finance.yahoo.comMadrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver FibrosisSee More Headlines Receive MDGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MDGL Company Calendar Last Earnings8/08/2023Today9/24/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:MDGL CUSIP87162T20 CIK1157601 Webwww.madrigalpharma.com Phone(267) 824-2827Fax781-274-8228Employees92Year Founded2011Price Target and Rating Average Stock Price Forecast$309.18 High Stock Price Forecast$390.00 Low Stock Price Forecast$224.00 Forecasted Upside/Downside+101.6%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($18.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-295,350,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-285.72% Return on Assets-114.11% Debt Debt-to-Equity Ratio0.96 Current Ratio3.02 Quick Ratio3.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.54 per share Price / Book13.29Miscellaneous Outstanding Shares18,470,000Free Float14,053,000Market Cap$2.83 billion OptionableOptionable Beta-0.72 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Rebecca A. Taub M.D. (Age 71)Founder, Chief Medical Officer, Pres of R&D and Director Comp: $939.83kMr. Alex G. Howarth (Age 54)Sr. VP & CFO Comp: $757.26kMr. Brian J. Lynch J.D. (Age 61)Sr. VP & Gen. Counsel Comp: $763.75kMr. Remy Sukhija (Age 51)Sr. VP & Chief Commercial Officer Comp: $785.2kMr. William J. Sibold (Age 57)CEO & Director Dr. Kianoush Motesharei Ph.d. (Age 53)Sr. VP of Bus. & Corp. Devel. Mr. Edward ChiangSr. VP of Clinical & Technical OperationsMr. Thomas W. HareSr. VP of Clinical ManagementDr. Robert E. Waltermire Ph.D. (Age 59)Chief Pharmaceutical Devel. Officer Dr. Stephen Dodge M.B.A.Pharm.D., Sr. VP of Global Medical AffairsMore ExecutivesKey CompetitorsAmicus TherapeuticsNASDAQ:FOLDImmunoGenNASDAQ:IMGNDynavax TechnologiesNASDAQ:DVAXIronwood PharmaceuticalsNASDAQ:IRWDOPKO HealthNASDAQ:OPKView All CompetitorsInsiders & InstitutionsPerceptive Advisors LLCSold 347,575 shares on 8/24/2023Ownership: 1.640%Wolverine Trading LLCBought 4,200 shares on 8/23/2023Ownership: 0.000%California State Teachers Retirement SystemBought 447 shares on 8/21/2023Ownership: 0.085%Osaic Holdings Inc.Bought 77 shares on 8/21/2023Ownership: 0.002%Verity Asset Management Inc.Bought 492 shares on 8/16/2023Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions MDGL Stock - Frequently Asked Questions Should I buy or sell Madrigal Pharmaceuticals stock right now? 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MDGL shares. View MDGL analyst ratings or view top-rated stocks. What is Madrigal Pharmaceuticals' stock price forecast for 2023? 11 analysts have issued twelve-month price objectives for Madrigal Pharmaceuticals' shares. Their MDGL share price forecasts range from $224.00 to $390.00. On average, they predict the company's share price to reach $309.18 in the next year. This suggests a possible upside of 101.6% from the stock's current price. View analysts price targets for MDGL or view top-rated stocks among Wall Street analysts. How have MDGL shares performed in 2023? Madrigal Pharmaceuticals' stock was trading at $290.25 on January 1st, 2023. Since then, MDGL shares have decreased by 47.2% and is now trading at $153.34. View the best growth stocks for 2023 here. When is Madrigal Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our MDGL earnings forecast. How were Madrigal Pharmaceuticals' earnings last quarter? Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) issued its earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($4.69) EPS for the quarter, missing analysts' consensus estimates of ($4.59) by $0.10. What ETFs hold Madrigal Pharmaceuticals' stock? ETFs with the largest weight of Madrigal Pharmaceuticals (NASDAQ:MDGL) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Alger Mid Cap 40 ETF (FRTY), Principal Healthcare Innovators ETF (BTEC) and iShares U.S. Pharmaceuticals ETF (IHE).Invesco Nasdaq Biotechnology ETF (IBBQ). What other stocks do shareholders of Madrigal Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Ayala Pharmaceuticals (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild). What is Madrigal Pharmaceuticals' stock symbol? Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL." Who are Madrigal Pharmaceuticals' major shareholders? Madrigal Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (5.65%), State Street Corp (2.94%), Assenagon Asset Management S.A. (2.55%), Marshall Wace LLP (2.49%), Alliancebernstein L.P. (2.01%) and Perceptive Advisors LLC (1.64%). Insiders that own company stock include Brian Joseph Lynch, Remy Sukhija and Richard S Levy. View institutional ownership trends. How do I buy shares of Madrigal Pharmaceuticals? Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Madrigal Pharmaceuticals' stock price today? One share of MDGL stock can currently be purchased for approximately $153.34. How much money does Madrigal Pharmaceuticals make? Madrigal Pharmaceuticals (NASDAQ:MDGL) has a market capitalization of $2.83 billion. The biopharmaceutical company earns $-295,350,000.00 in net income (profit) each year or ($18.65) on an earnings per share basis. How can I contact Madrigal Pharmaceuticals? Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The official website for the company is www.madrigalpharma.com. The biopharmaceutical company can be reached via phone at (267) 824-2827, via email at ir@madrigalpharma.com, or via fax at 781-274-8228. This page (NASDAQ:MDGL) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.